Consultancies at ACT 2026

Nov 15–18, 2026 San Antonio, TX ~1.4k attendees Website

37 consultancies are at ACT 2026 — 38 presentations on the program and 6 with a booth in the exhibit hall. Most represented: ToxStrategies (3 on the program), White Oak Regulatory Tox (2 on the program), Akkeri (2 on the program). 24 of them have their own page in this guide. As of Oct 8, 2026.

All 231 organizations at ACT 2026 →

Topic
Top represented
Showing 1–15 of 37 organizations
OrganizationACT 2026 Attendance
ToxStrategies
Rancho Santa Margarita, CA
◆Gold Supporter
ConsultanciesGold Supporter
Consultancy, part of BlueRidge Life Sciences, that plans and manages nonclinical programs across small molecules, biologics and cell and gene therapies.
Booth
Exhibiting at Booth 606
Mon, Nov 169:30am–6:30pmTue, Nov 178:00am–4:30pm
Talk
Mon Nov 16
9:05am–9:25am
Part of The Role of Professional Judgment in Toxicology amidst the Rise of Artificial Intelligence and Computational Tools (S02)
Enhancing Toxicological Literature Review through AI and Expert Insight (S02-2)
In silico and AI
Talk
Mon Nov 16
9:45am–10:15am
Part of Beyond the Vessel Wall: Translational Insights into Vascular Inflammation (S03)
A Regulatory Perspective (S03-3)
Regulatory
Poster
Mon Nov 16
5:00pm–6:30pm
◇Bronze Supporter
ConsultanciesBronze Supporter
Consultancy run by former FDA reviewers on nonclinical strategy, regulatory toxicology, pre-review of filings and asset due diligence.
Talk
Sun Nov 15
8:00am–8:20am
Part of First-in-Human Dose Selection: Translational Strategies and Special Considerations across Modalities and Organ Systems (CE1)
Foundational Approaches to FIH Dose Selection (CE1-1)
Translational safety
Talk
Wed Nov 18
9:15am–9:45am
Part of The Future of Nonclinical Carcinogenicity Testing: NAMs in a Weight-of-Evidence Paradigm Shift (S15)
Carcinogenicity Assessments Based on a Weight of Evidence Approach and the Role of NAMs in Supporting This Approach (S15-2)
Genetic toxicology · New approach methods
Consultancies
Nonclinical drug development consultancy whose team includes former FDA reviewers, covering cell and gene therapies, oligonucleotides, biologics and small molecules.
Talk
Sun Nov 15
8:45am–9:10am
Part of First-in-Human Dose Selection: Translational Strategies and Special Considerations across Modalities and Organ Systems (CE1)
CNS-Delivered Therapeutics: Anatomic, Physiologic, and Modality-Specific Considerations (CE1-3)
Translational safety · Neurotoxicology
Talk
Tue Nov 17
10:45am–11:15am
Part of What Did You Forget on Your Way to Your NDA/MAA? Strategic Considerations for Late-Stage Nonclinical Safety Studies (S09)
Applying Weight-of-Evidence and Waivers for Late-Stage Nonclinical Safety Studies (S09-5)
Regulatory
Consultancies
Toxicologic pathology consultancy evaluating GLP nonclinical study pathology for drug developers and contract research organizations.
Talk
Mon Nov 16
10:45am–11:20am
Part of From China to the World: De-risking Nonclinical Safety Packages to Ensure Regulatory Acceptance (S01)
Pathology Without Borders: Best Practices for Pathology Review and Digital Data Exchange in China (S01-3)
Pathology · Regulatory
Talk
Wed Nov 18
10:45am–11:05am
Part of Do You Hear What I Hear? Evaluating Otic and Vestibular Toxicity in Clinical Development (S14)
Pathology of Candidates Targeting Otic Conditions (S14-4)
Pathology · Neurotoxicology
Consultancies
Toxicology consultancy presenting on hazard classification of drug formulations and mutagenic impurity risk in veterinary drugs.
Poster
Mon Nov 16
5:00pm–6:30pm
Poster
Mon Nov 16
5:00pm–6:30pm
Risk Assessment of Potential Mutagenic Impurities in Veterinary Drugs (P211)
Nelson Exhibit Ballroom · Poster P211
Genetic toxicology · Chemical risk assessment
Consultancies
Consultancy offering pathology and immunology expertise for the immunosafety assessment of immunotherapies.
Talk
Sun Nov 15
1:00pm–1:30pm
Part of Immunotherapies and Collaborative Approaches to Immunosafety Assessment (CE6)
The Immunology Behind Developing and Evaluating New Immunotherapies (CE6-1)
Immunotoxicology
Talk
Sun Nov 15
3:20pm–4:30pm
Part of Immunotherapies and Collaborative Approaches to Immunosafety Assessment (CE6)
Round Table Discussion: Scientific Perspectives and Key Communication Considerations by Scientific Experts for an Immunosafety (Case Study) Scenario (CE6-Panel)
Immunotoxicology
ApconiX
Alderley Edge, UK
Consultancies
UK toxicology consultancy with its own lab: hERG and cardiac screening, in vitro seizure assays, target safety assessments and nonclinical regulatory support.
Booth
Exhibiting at Booth 213
Mon, Nov 169:30am–6:30pmTue, Nov 178:00am–4:30pm
Talk
Wed Nov 18
9:40am–10:15am
Part of Modernizing Drug Development: Advanced Translational Methodologies for CNS and PNS Risk Assessment (S13)
Mechanistic Insights into Species-Specific Seizure Susceptibility (S13-3)
Safety pharmacology · Neurotoxicology
Talk
Wed Nov 18
12:00pm–12:55pm
◇Bronze Supporter
ConsultanciesBronze Supporter
Consultancy giving regulatory and toxicology support for nonclinical development, including preparing for meetings with regulatory agencies.
Session
Sun Nov 15
8:00am–11:30am
Working with Global Regulators for Streamlined Nonclinical Development (CE4)
Regulatory · with Johnson & Johnson
  1. 8:00amIntroduction (CE4-1)Johnson & Johnson
  2. 8:05amTop Tips for Successful Nonclinical Regulatory Interaction (CE4-2)Charles River
  3. 8:30amIdeal Interaction During Drug Development: FDA Regulator's Perspective (CE4-3)U.S. Food and Drug Administration
  4. 9:00amIdeal Interaction During Drug Development: European Regulator's Perspective (CE4-4)Medicines Evaluation Board
  5. 10:00amSponsor Strategies for Successful Regulatory Agency Interactions (CE4-5)Lilly
  6. 10:30amInteractive Workshop: Practical Case Studies to Model Successful Regulatory Agency Interactions (CE4-6)MEC Regulatory & Toxicology Consulting
Talk
Sun Nov 15
10:30am–11:20am
Part of Working with Global Regulators for Streamlined Nonclinical Development (CE4)
Interactive Workshop: Practical Case Studies to Model Successful Regulatory Agency Interactions (CE4-6)
Regulatory
Consultancies
ADME and toxicology consultancy presenting on model-informed first-in-human dose prediction and getting drugs into the brain.
Talk
Sun Nov 15
8:20am–8:45am
Part of First-in-Human Dose Selection: Translational Strategies and Special Considerations across Modalities and Organ Systems (CE1)
Model-Informed Approaches to FIH Dose Prediction (CE1-2)
Translational safety · with Tango Therapeutics
Talk
Tue Nov 17
9:05am–9:30am
Part of Overcoming the Blood-Brain Barrier and Translational Challenges in the Nonclinical Development of CNS Drugs (S08)
Beyond the Barrier: Unlocking Drug Penetration into the CNS (S08-2)
Neurotoxicology
◇Bronze Supporter
ConsultanciesBronze Supporter
Long-running toxicology consultancy supporting drug and medical device development with study design, statistics and risk assessment.
Poster
Mon Nov 16
5:00pm–6:30pm
Tolerated Vehicle Levels in Pregnant Rabbits (Developmental Studies) and Minipigs: Part of 2026 Vehicles Codex (P443)
Nelson Exhibit Ballroom · Poster P443
Chemical risk assessment · DART
◆Gold Supporter
ConsultanciesGold Supporter
Consultancy helping small and mid-sized drug, biotech and device companies meet FDA requirements, from preclinical planning through post-approval.
◇Bronze Supporter
ConsultanciesBronze Supporter
Independent consultancy offering nonclinical toxicology strategy, GLP toxicokinetic reporting and in silico toxicity predictions for pharmaceutical developers.
Booth
Exhibiting at Booth 600
Mon, Nov 169:30am–6:30pmTue, Nov 178:00am–4:30pm
Talk
Sun Nov 15
1:30pm–2:00pm
Part of Navigating Genetic Toxicology through Drug Development: Interface of Practice, Strategy, and Regulatory Principles (CE7)
A Practical Guide to the Implementation of ICH M7 (CE7-2)
Genetic toxicology · Regulatory
Bioepisteme
Irvine, CA
Consultancies
Drug development consultancy advising on nonclinical pharmacology and toxicology, IND-enabling studies and clinical pharmacokinetics, with a focus on biologics.
Talk
Mon Nov 16
3:45pm–4:20pm
Part of Navigating Safety Signals and Clinical Holds: Lessons Learned from Nonclinical and Clinical Development (S06)
Clinical Holds in the Development of Novel Genetic Medicines (S06-4)
Translational safety · Biologics and new modalities
Biologics Consulting
Alexandria, VA
Consultancies
Regulatory and product development consultancy for biologics, drugs and devices, with nonclinical pharmacology-toxicology, clinical and manufacturing support.
Talk
Wed Nov 18
2:40pm–3:00pm
Part of The Versatile Toxicologist: How to Leverage Expertise into Opportunity (S16)
So You Want to Be a Consultant? (S16-3)
Careers
BiotechGo
Beijing, China
Consultancies
Toxicology and regulatory consultancy in Beijing that selects and audits Chinese CROs and monitors studies for biotech clients.
Talk
Mon Nov 16
9:00am–9:40am
Part of From China to the World: De-risking Nonclinical Safety Packages to Ensure Regulatory Acceptance (S01)
Working with Chinese CROs: Benefits, Risks and Best Practices (S01-1)
Regulatory

Explore the full ACT 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in San Antonio. Leave your work email and we’ll be in touch.

Privacy

Download the full ACT 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from consultancies

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Browse ACT 2026 by

Exhibit hall

Not affiliated with or endorsed by the American College of Toxicology (ACT). Organization details are derived from ACT’s published program, exhibitor floor plan and supporter list, and each organization’s own website. Submit a correction